Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in pediatric relapsed high-grade MDS or JMML
NL-OMON47695Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine in myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) (2 arms), sponsored by Erasmus MC. Primary endpoint: Recommended dose, safety, and preliminary efficacy of azacitidine. Started Jul 2012; status: recruiting.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NL-OMON47695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47695.